Literature DB >> 18055460

Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity.

Cristina Bergamaschi1, Margherita Rosati, Rashmi Jalah, Antonio Valentin, Viraj Kulkarni, Candido Alicea, Gen-Mu Zhang, Vainav Patel, Barbara K Felber, George N Pavlakis.   

Abstract

We show that co-expression of interleukin 15 (IL-15) and IL-15 receptor alpha (IL-15Ralpha) in the same cell allows for the intracellular interaction of the two proteins early after translation, resulting in increased stability and secretion of both molecules as a complex. In the absence of co-expressed IL-15Ralpha, a large portion of the produced IL-15 is rapidly degraded immediately after synthesis. Co-injection into mice of IL-15 and IL-15Ralpha expression plasmids led to significantly increased levels of the cytokine in serum as well as increased biological activity of IL-15. Examination of natural killer cells and T lymphocytes in mouse organs showed a great expansion of both cell types in the lung, liver, and spleen. The presence of IL-15Ralpha also increased the number of CD44(high) memory cells with effector phenotype (CD44(high)CD62L-). Thus, mutual stabilization of IL-15 and IL-15Ralpha leads to remarkable increases in production, stability, and tissue availability of bioactive IL-15 in vivo. The in vivo data show that the most potent form of IL-15 is as part of a complex with its receptor alpha either on the surface of the producing cells or as a soluble extracellular complex. These results explain the reason for coordinate expression of IL-15 and IL-15Ralpha in the same cell and suggest that the IL-15Ralpha is part of the active IL-15 cytokine rather than part of the receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055460     DOI: 10.1074/jbc.M705725200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation.

Authors:  Qiang Liu; Nader Sanai; Wei-Na Jin; Antonio La Cava; Luc Van Kaer; Fu-Dong Shi
Journal:  Nat Neurosci       Date:  2016-01-11       Impact factor: 24.884

2.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Authors:  John M Wrangle; Vamsidhar Velcheti; Manish R Patel; Elizabeth Garrett-Mayer; Elizabeth G Hill; James G Ravenel; Jeffrey S Miller; Mohammad Farhad; Kate Anderton; Kathryn Lindsey; Michele Taffaro-Neskey; Carol Sherman; Samantha Suriano; Marzena Swiderska-Syn; Amy Sion; Joni Harris; Andie R Edwards; Julie A Rytlewski; Catherine M Sanders; Erik C Yusko; Mark D Robinson; Carsten Krieg; William L Redmond; Jack O Egan; Peter R Rhode; Emily K Jeng; Amy D Rock; Hing C Wong; Mark P Rubinstein
Journal:  Lancet Oncol       Date:  2018-04-05       Impact factor: 41.316

3.  IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.

Authors:  Kai-ping Han; Xiaoyun Zhu; Bai Liu; Emily Jeng; Lin Kong; Jason L Yovandich; Vinay V Vyas; Warren D Marcus; Pierre-Andre Chavaillaz; Christian A Romero; Peter R Rhode; Hing C Wong
Journal:  Cytokine       Date:  2011-10-22       Impact factor: 3.861

4.  Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.

Authors:  Yu-Jin Lee; Xiaozhen Zhang; Estefania Vazquez; Gayathri Shivasabesan; Howard A Young; Alison Murphy; Honghui Wang; Anthony F Suffredini; Ulrich Siebenlist; Shyam Kottilil
Journal:  J Interferon Cytokine Res       Date:  2013-10-30       Impact factor: 2.607

5.  CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans.

Authors:  Adam T Waickman; Davinna L Ligons; SuJin Hwang; Joo-Young Park; Vanja Lazarevic; Noriko Sato; Changwan Hong; Jung-Hyun Park
Journal:  Cytokine       Date:  2017-08-12       Impact factor: 3.861

6.  Efficient production and enhanced tumor delivery of engineered extracellular vesicles.

Authors:  Dionysios C Watson; Defne Bayik; Avinash Srivatsan; Cristina Bergamaschi; Antonio Valentin; Gang Niu; Jenifer Bear; Mitchell Monninger; Mei Sun; Aizea Morales-Kastresana; Jennifer C Jones; Barbara K Felber; Xiaoyuan Chen; Ihsan Gursel; George N Pavlakis
Journal:  Biomaterials       Date:  2016-07-06       Impact factor: 12.479

7.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27

8.  Dendritic cells drive memory CD8 T-cell homeostasis via IL-15 transpresentation.

Authors:  Spencer W Stonier; Lisa J Ma; Eliseo F Castillo; Kimberly S Schluns
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

9.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

10.  Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.

Authors:  Jesse Rowley; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.